Human Vascular Endothelial Growth Factor Receptor 1 (Vegfr-1) Fragment 129-228 Comprising The Second Extracellular Domain Of The Vegf Receptor (Vegfr-D2), [N<Sup>196</Sup>>A<Sup>68</Sup>]-Variant, Anti-(Human Vascular Endothelial Growth Factor (Vegf) (1-100 In The Current Sequence) Fused, Via A (G4S)3 Peptide Linker (101-115), To Gamma 1 Heavy Chain (116-563) [Vh (Homo Sapiens Ighv3-23*04 -(Ighd) -Ighj4*01, Cdr-Kabat [5.17.9] (146-150.165-181.214-222)) (116-233) -Homo Sapiens Ighg1*03 (Ch1 (234-331), Hinge (332-346), Ch2 S<Sup>414</Sup>>A, E<Sup>449</Sup>>A, K<Sup>450</Sup>>A (347-456), Ch3 (457-561), Chs (562-563)) (234-563)], (336-214')-Disulfide With Kappa Light Chain (1'-214') [V-Kappa (Homo Sapiens Igkv1-12*01 -Igkj1*01, Cdrkabat [11.7.9] (24'-34'.50'-56'.89'-97')) (1'-107') -Homo Sapiens Igkc*01 (108'-214')]; Dimer (342-342'', 345-345'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa
Cancer
Explore 1,380 assets in Cancer →Floatz Rating
CC45/100
Confidence
Indicative
Sponsor
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Modality
protein_peptide
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
40Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07170787CT.gov A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT06764836CT.gov A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05972460CT.gov IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Human Vascular Endothelial Growth Factor Receptor 1 (Vegfr-1) Fragment 129-228 Comprising The Second Extracellular Domain Of The Vegf Receptor (Vegfr-D2), [N<Sup>196</Sup>>A<Sup>68</Sup>]-Variant, Anti-(Human Vascular Endothelial Growth Factor (Vegf) (1-100 In The Current Sequence) Fused, Via A (G4S)3 Peptide Linker (101-115), To Gamma 1 Heavy Chain (116-563) [Vh (Homo Sapiens Ighv3-23*04 -(Ighd) -Ighj4*01, Cdr-Kabat [5.17.9] (146-150.165-181.214-222)) (116-233) -Homo Sapiens Ighg1*03 (Ch1 (234-331), Hinge (332-346), Ch2 S<Sup>414</Sup>>A, E<Sup>449</Sup>>A, K<Sup>450</Sup>>A (347-456), Ch3 (457-561), Chs (562-563)) (234-563)], (336-214')-Disulfide With Kappa Light Chain (1'-214') [V-Kappa (Homo Sapiens Igkv1-12*01 -Igkj1*01, Cdrkabat [11.7.9] (24'-34'.50'-56'.89'-97')) (1'-107') -Homo Sapiens Igkc*01 (108'-214')]; Dimer (342-342'', 345-345'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa (this asset) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | P1/2 | CC · 45 |
| Nabiximols | Jazz Pharmaceuticals | P3 | BBB |
| Pyridoxol | M.D. Anderson Cancer Center | P4 | BB |
| Rivoceranib | Jiangsu HengRui Medicine Co., Ltd. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Propofol | Hong Kong Children's Hospital | P4 | BB |
| Epirubicin | Zhejiang Provincial People's Hospital | P3 | BB |
| Atorvastatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P2/3 | BB |
| Anamorelin | Helsinn Healthcare SA | P3 | BB |
+42 more in the Cancer cohort
Other indications for Human Vascular Endothelial Growth Factor Receptor 1 (Vegfr-1) Fragment 129-228 Comprising The Second Extracellular Domain Of The Vegf Receptor (Vegfr-D2), [N<Sup>196</Sup>>A<Sup>68</Sup>]-Variant, Anti-(Human Vascular Endothelial Growth Factor (Vegf) (1-100 In The Current Sequence) Fused, Via A (G4S)3 Peptide Linker (101-115), To Gamma 1 Heavy Chain (116-563) [Vh (Homo Sapiens Ighv3-23*04 -(Ighd) -Ighj4*01, Cdr-Kabat [5.17.9] (146-150.165-181.214-222)) (116-233) -Homo Sapiens Ighg1*03 (Ch1 (234-331), Hinge (332-346), Ch2 S<Sup>414</Sup>>A, E<Sup>449</Sup>>A, K<Sup>450</Sup>>A (347-456), Ch3 (457-561), Chs (562-563)) (234-563)], (336-214')-Disulfide With Kappa Light Chain (1'-214') [V-Kappa (Homo Sapiens Igkv1-12*01 -Igkj1*01, Cdrkabat [11.7.9] (24'-34'.50'-56'.89'-97')) (1'-107') -Homo Sapiens Igkc*01 (108'-214')]; Dimer (342-342'', 345-345'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Triple-Negative Breast Carcinoma | — | P2 | CCC · 53 |
| Non-Small Cell Lung Carcinoma | — | P2 | CCC · 48 |
| Hepatocellular Carcinoma | — | P1 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Human Vascular Endothelial Growth Factor Receptor 1 (Vegfr-1) Fragment 129-228 Comprising The Second Extracellular Domain Of The Vegf Receptor (Vegfr-D2), [N<Sup>196</Sup>>A<Sup>68</Sup>]-Variant, Anti-(Human Vascular Endothelial Growth Factor (Vegf) (1-100 In The Current Sequence) Fused, Via A (G4S)3 Peptide Linker (101-115), To Gamma 1 Heavy Chain (116-563) [Vh (Homo Sapiens Ighv3-23*04 -(Ighd) -Ighj4*01, Cdr-Kabat [5.17.9] (146-150.165-181.214-222)) (116-233) -Homo Sapiens Ighg1*03 (Ch1 (234-331), Hinge (332-346), Ch2 S<Sup>414</Sup>>A, E<Sup>449</Sup>>A, K<Sup>450</Sup>>A (347-456), Ch3 (457-561), Chs (562-563)) (234-563)], (336-214')-Disulfide With Kappa Light Chain (1'-214') [V-Kappa (Homo Sapiens Igkv1-12*01 -Igkj1*01, Cdrkabat [11.7.9] (24'-34'.50'-56'.89'-97')) (1'-107') -Homo Sapiens Igkc*01 (108'-214')]; Dimer (342-342'', 345-345'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa in Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/human-vascular-endothelial-growth-factor-receptor-1-vegfr-1-fragment-129-228-comprising-the-second-extracellular-domain-of-the-vegf-receptor-vegfr-d2-nsup196supasup68sup-variant-anti-human-vascular-endothelial-growth-factor-vegf-1-100-in-the-current-sequence-fused-via-a-g4s3-peptide-linker-101-115-to-gamma-1-heavy-chain-116-563-vh-homo-sapiens-ighv3-2304-ighd-ighj401-cdr-kabat-5179-146-150165-181214-222-116-233-homo-sapiens-ighg103-ch1-234-331-hinge-332-346-ch2-ssup414supa-esup449supa-ksup450supa-347-456-ch3-457-561-chs-562-563-234-563-336-214-disulfide-with-kappa-light-chain-1-214-v-kappa-homo-sapiens-igkv1-1201-igkj101-cdrkabat-1179-24-3450-5689-97-1-107-homo-sapiens-igkc01-108-214-dimer-342-342-345-345-bisdisulfide-produced-in-chinese-hamster-ovary-cho-cells-cell-line-cho-k1-glycoform-alfa-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →